South Korea Approves Yunque Newtech's Velsipity for Moderate-to-Severe Ulcerative Colitis

GateNews
Yunque Newtech announced that South Korea's Ministry of Food and Drug Safety (MFDS) has approved Velsipity (efinaconazole) for treating adults with moderate-to-severe active ulcerative colitis who have inadequate response, loss of response, or intolerance to conventional therapies such as corticosteroids, immunosuppressants, or biologics.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments